An Introduction to Hepatology
Hepatology covers hepatitis, hepatocellular carcinoma (HCC), nonalcoholic fatty liver disease (NAFLD), cirrhosis and rarer conditions such as autoimmune and cholestatic liver diseases. Despite numerous advances, liver-related mortality has remained stable for over 30 years. The World Health Organization has set targets for hepatitis C elimination by 2030. Immunotherapy and combination therapies have greatly increased the efficacy of the treatment of hepatocellular carcinoma (HCC). However, as a result of the increasing prevalence of obesity, NAFLD is reaching epidemic proportions and poses a major challenge to global public health. There is an urgent need for long-term management strategies and pharmacological interventions for NAFLD.
Our supporting partners do not constitute an endorsement of the content on this page.
Achieving best practice management of primary biliary cholangitis, now and in the future
Watch two specialists in autoimmune liver disease discuss best practice in the management of primary biliary cholangitis, including assessing emerging therapies and personalization of care.
- Describe the recommendations for diagnosis and management of patients with primary biliary cholangitis
- Evaluate emerging treatment options for patients with primary biliary cholangitis
- Review and implement individualized management for patients with primary biliary cholangitis
Arjan Bredenoord, UEG Week 2022: Analysis of the LIBERTY-EoE-TREET study of dupilumab in eosinophilic esophagitis
LIBERTY-EoE-TREET (NCT03633617) was a phase 3, randomized, 3-part study investigating the efficacy and safety of dupilumab in eosinophilic esophagitis (EoE). It was a pleasure to talk with Prof. Arjan Bredenoord (Amsterdam UMC, Amsterdam, the Netherlands) around his analysis of the LIBERTY-EoE-TREET study, looking at the efficacy of dupilumab in patients with EoE with and without […]
Maria Buti, EASL ILC 2022: Impact of bulevirtide on patient-reported outcomes
MYR301 (NCT03852719) is a phase 3 study evaluating the long-term efficacy and safety of bulevirtide in people living with chronic hepatitis delta infection (CHD). In this interview, Prof. Maria Buti (Vall d’Hebron University Hospital, Barcelona, Spain) discusses the results from the exploratory analysis of MYR301, investigating the health-related quality of life (HRQOL) benefits of treatment […]
Thomas Berg, EASL: Unmet needs in diagnosis and treatment of hepatitis
touchIMMUNOLOGY spoke with Prof. Thomas Berg (University Hospital Leipzig, Leipzig, Germany; Secretary General, EASL) to discuss the burden of hepatitis, the path to diagnosis, and the current treatment options available for hepatitis B, C, and D. Question: What are the unmet needs in diagnosis and treatment of hepatitis? (0:20) Disclosures: Dr Thomas Berg has received grant/research […]
Nancy Reau, DDW 2021: Hepatic Manifestations of COVID-19
It was a pleasure to speak with Prof. Nancy Reau (Rush Medical College, Chicago, IL, USA) about the hepatic manifestations of COVID-19 infection. Her presentation entitled ‘HEPATIC MANIFESTATIONS OF COVID-19: IS THERE CAUSE FOR CONCERN?’ was given at DDW, 21-23 May 2021 May 2021. Questions Could you give us a brief overview of the spectrum […]
Peter C Taylor, ACR 2020 – HCQ in the prevention of NAFLD (Part 2)
In Part 2 of our ACR Convergence Highlights coverage, Peter C Taylor (University of Oxford, Oxford, UK) discusses the results of an exploratory study into the association of Hydroxychloroquine (HCQ) use and the development of Non-Alcoholic Fatty Liver Disease (NAFLD) in patients with RA. The full abstract ‘Association of Hydroxychloroquine Use with Development of Non-Alcoholic […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!